

IBD Patient News



MICHIGAN MEDICINE
UNIVERSITY OF MICHIGAN

Winter 2017/2018

U-M Division of Gastroenterology

Pt Education on the Road

Each of these events provide an opportunity for patients and their families to come together and learn more about IBD. Presentations are done by University of Michigan physicians and a meal is provided.

If you are interested in attending, contact:

higginsSCteam@umich.edu

Upcoming IBD Pt Events

Frankenmuth

December 14th, 2017

Dearborn

January 11th, 2018

Grand Rapids

March 14th, 2018



Save the Date!

Our annual Patient-2-Patient education Program brings both IBD patients, their families, and IBD physicians together.

Join us on March 24th, 2018.

For more information contact:

higginsSCteam@umich.edu

A Convenient New Way to See Your IBD Specialist

We are now actively using the IBD Telemedicine Program. Established patients with an IBD specialist can request return telemedicine visits. This requires that you have a rapid internet connection, a computer with a webcam, and the ability to download software to your computer. The clerks will confirm these criteria when they check you out of clinic, and will schedule a telemedicine visit when you leave. You will receive a reminder for your visit, and will need to have your computer set up and your webcam ready to go 5 minutes before the visit time. You will be able to see your doctor, and your doctor will be able to see you, and discuss how you are doing and your ongoing care. You are still required to be seen in clinic once per year, and for urgent visits. Ask your doctor if an IBD telemedicine visit would be appropriate for your next follow up visit.

Currently Enrolling Clinical Trials

Ulcerative Colitis

Hickory—etrolizumab

Subcutaneous Injection

This is a phase three study for patients with moderate to severely active Ulcerative Colitis to evaluate the safety and effectiveness of etrolizumab, which targets anti-integrin b7.

ABT494—Upadacitinib

Oral tablet

This is a phase 2b/3 study for patients with moderate to severe Ulcerative Colitis to evaluate the safety and effectiveness of a new medication targeting JAK1.

Upstart—LY30937

Oral tablet

This is a phase 2 study to evaluate the safety and effectiveness while inducing remission in patients with moderate to severe Ulcerative Colitis over the course of 8 weeks.

Legacy

Observational

This is an observational study for patients who are taking Humira for up to 10 years. This is to observe the safety of long term use of Humira for patients who have Ulcerative Colitis.

Crohn's Disease

Bergamont—etrolizumab

Subcutaneous Injection

This is a phase three study for patients with moderate to severely active Crohn's disease to evaluate the safety and effectiveness of etrolizumab, which targets anti-integrin b7.

PIONEER

Medical Food Supplement

This study is to evaluate the effectiveness of an orally administered medical food in moderately to severely active subjects receiving induction therapy for Remicade or Humira.

Dine CD

Dietary

This study is to compare the effectiveness of a specific carbohydrate diet and Mediterranean style diet to induce symptoms and clinical remission in patients with active Crohns disease.

APD371—cannabinoid receptor agonist

Oral tablet

This is a phase 2a study to determine the tolerability and effectiveness of APD371 in patients who have mildly active Crohns disease with abdominal pain.

Lilly—LY3074828

IV Induction / Subcutaneous injection for maintenance

This is a phase two study for patients with moderate to severe Crohn's disease to evaluate the safety and effectiveness of a new medication targeting interleukin-23.

Coming Soon:

ABT494—Upadacitinib

This is a study for patients with moderate to severe Crohns disease.

ABBV-066—Risankizumab

This is a study for patients with moderate to severe Crohns disease.

WE NEED YOU!

In addition to the clinical trials we have available, there are many other kinds of research going on within our group. We are always looking for volunteers who are willing to provide samples (i.e. stool, blood, biopsies from colonoscopies). Sometimes, we may just need someone willing to fill out a survey every few months. Whatever your comfort level, we likely have a study that would suit you.

Your non-IBD friends and family don't have to feel left out either. There are plenty of opportunities for healthy controls to contribute to our research. Contact us at higginsSCTeam@umich.edu.